Imatinib
B-cell Childhood Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the B-cell Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE St. Jude Children's Research Hospital | Phase 3 | A |
MERCAPTOPURINE ANHYDROUS St. Jude Children's Research Hospital | Phase 3 | A |
PEGASPARGASE St. Jude Children's Research Hospital | Phase 3 | A |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
METHOTREXATE St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 44 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →